97056 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
#1502Truncated activin type II receptor and methods of use
#1503HER3 AS A DETERMINANT FOR THE PROGNOSIS OF MELANOMA
#1504PROSPECTIVE IDENTIFICATION AND CHARACTERIZATION OF BREAST CANCER STEM CELLS
#1505Modified Chimeric Polypeptides with Improved Pharmacokinetic Properties
#1506Method for the administration of anti-cancer drugs
#1507CRYSTAL STRUCTURE OF THE COMPLEX OF HEPATOCYTE GROWTH FACTOR BETA CHAIN WITH MET RECEPTOR AND METHODS OF USE
#1508Cripto antagonism of activin and TGF-b signaling
#1509MODULATORS AND MODULATION OF THE INTERACTION BETWEEN RGM AND NEOGENIN
#1510REGULATED TRANSCRIPTION OF TARGETED GENES AND OTHER BIOLOGICAL EVENTS
#1511ANTAGONISTS OF NEUROPILIN RECEPTOR FUNCTION AND USE THEREOF
#1512Anti-angiogenesis fusion proteins
#1513Antibodies which bind specifically to activin receptor like kinase 3
#1514Regulated apoptosis
#1515IMMUNOGENIC COMPOUNDS AND PROTEIN MIMICS
#1516Antibodies to EGF receptor epitope peptides and uses thereof
#1517ALK7 AND MYOSTATIN INHIBITORS AND USES THEREOF
#1518Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
#1519Isolated nucleic acid encoding a truncated ActRIIB fusion protein
#1520USES OF GDNF AND GDNF RECEPTOR
#1521HLA-DR BINDING PEPTIDES AND THEIR USES
#1522Methods for increasing thermogenic adipocytes
#1523VACCINE THERAPY FOR CHOROIDAL NEOVASCULARIZATION
#1524Immunogenic HER-2 variants
#1525PRO34128 nucleic acids
#1526VEGF antagonist formulations
#1527Method of treating a disease or condition characterized by aberrant epithelial cell proliferation
#1528Alpha 1-acid glycoprotein, alpha 2-HS glycoprotein, alpha 1-antitrypsin, and fragments thereof induce apoptosis in cancer cell lines
#1529Method of identifying transmembrane protein-interacting compounds
#1530COMPOSITIONS COMPRISING OPTIMIZED HER1 AND HER3 MULTIMERS AND METHODS OF USE THEREOF
#1531Methods of screening for neoplastic disease states
#1532Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
#1533Soluble inhibitors of vascular endothelial growth factor and use thereof
#1534Actriib-Fc polynucleotides, polypeptides, and compositions
#1535BMP-ALK3 antagonists and uses for promoting bone growth
#1536WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS
#1537TACI-IMMUNOGLOBULIN FUSION PROTEINS FOR TREATMENT OF RELAPSING MULTIPLE SCLEROSIS
#1538GFRALPHA3 AND ITS USES
#1539Peptide antagonists of vascular endothelial growth factor and methods of use thereof
#1540ErbB interface peptidomimetics and methods of use thereof
#1541IMMUNOGENIC EPITOPES, PEPTIDOMIMETICS, AND ANTI-PEPTIDE ANTIBODIES, AND METHODS OF THEIR USE
#1542Fusion polypeptides capable of activating receptors
#1543Targeting vector-phospholipid conjugates
#1544Peptidic antagonists of class III semaphorins/neuropilins complexes
#1545Isolated nucleic acid molecules encoding a fusion protein capable of binding VEGF
#1546Tumor marker
#1547KDR peptides and vaccines comprising the same
#1548Modulation of activity of proneurotrophins
#1549Vaccine for the prevention of breast cancer relapse
#1550Deglycosylated and desialidated long pentraxin PTX3
#1551FUSION PROTEINS CONTAINING TWO TGF-BETA BINDING DOMAINS OF TGF-BETA TYPE II RECEPTOR
#1552Activin-actrii antagonists and uses for increasing red blood cell levels
#1553TARGETS FOR TUMOR GROWTH INHIBITION
#1554Growth hormone fusion proteins
#1555Inhibition of palmitoyl acyl transferase expression and/or activity for the regulation of antiproliferative factor activity
#1556Masking Ligands For Reversible Inhibition Of Multivalent Compounds
#1557MONOCLONAL ANTIBODIES TO ACTIVATED ERBB FAMILY MEMBERS AND METHODS OF USE
#1558Method of diagnosing an RTK-hyperfunction induced disorder
#1559Sequential administration of a replication defective adenovirus vector in vaccination protocols
#1560Methods for increasing adiponectin in a patient in need thereof
#1561HEPATOCYTE GROWTH FACTOR RECEPTOR SPLICE VARIANTS AND METHODS OF USING SAME
#1562SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS
#1563Receptor-based interaction trap
#1564Methods of increasing muscle mass using follistatin-like related gene (FLRG)
#1565Stabilized activin IIB receptor polypeptides and uses thereof
#1566Transgenic mice expressing humanized VEGF
#1567KLOTHO BETA
#1568FGFR3-IIIc fusion proteins
#1569Wound healing
#1570Fusion protein capable of binding VEGF-A and TNF-alpha
#1571Anti-pan neuropilin antibody and binding fragments thereof
#1572VARIANTS OF VEGFR AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF PREGNANCY ASSOCIATED MEDICAL CONDITIONS
#1573Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
#1574ErbB2 and ErbB3 chimeric heteromultimer receptors
#1575Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
#1576ErbB interface peptidomimetics and methods of use thereof
#1577Antagonist of ligands and uses thereof
#1578COMPOSITIONS AND METHODS FOR TREATING CANCER BY MODULATING HER-2 AND EGF RECEPTORS
#1579ONCOKINASE FUSION POLYPEPTIDES ASSOCIATED WITH HYPERPROLIFERATIVE AND RELATED DISORDERS, NUCLEIC ACIDS ENCODING THE SAME AND METHODS FOR DETECTING AND IDENTIFYING THE SAME
#1580Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein
#1581PLEIOTROPHIN GROWTH FACTOR RECEPTOR FOR THE TREATMENT OF PROLIFERATIVE, VASCULAR AND NEUROLOGICAL DISORDERS
#1582Antibodies to notch receptors
#1583Dimeric high affinity EGFR constructs and uses thereof
#1584PEPTIDE THERAPEUTICS THAT BIND VEGF AND METHODS OF USE THEREOF
#1585USE OF NOVEL CYTOKINE RECEPTORS AS BIOMARKERS AND THERAPEUTIC TARGETS IN HUMAN CANCER
#1586VEGF-binding fusion proteins and therapeutic uses thereof
#1587FGFR extracellular domain acidic region muteins
#1588IMMUNE REACTIVITY TO HER-2/NEU PROTEIN FOR DIAGNOSIS AND TREATMENT OF MALIGNANCIES IN WHICH THE HER-2/NEU ONCOGENE IS ASSOCIATED
#1589Glycan modified soluble receptors and binding protein and their use
#1590CO-CRYSTAL OF ANTIBODY 11F8FAB FRAGMENT AND EGFR EXTRACELLULAR DOMAIN AND USES THEREOF
#1591ErbB interface peptidomimetics and methods of use thereof
#1592Lyophilized VEGF antagonist formulations for intravitreal administration
#1593Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of Sp35 or TrkA antagonists
#1594Transgenic non-human animals expressing a truncated activin type II receptor
#1595Modified soluble FGF receptor Fc fusions with improved biological activity
#1596PAN-CELL SURFACE RECEPTOR-SPECIFIC THERAPEUTICS
#1597Active antiangiogenic therapy
#1598Antagonists of actriib and uses for increasing red blood cell levels
#1599Antagonists of activin-actriia and uses for increasing red blood cell levels
#1600NoGo Receptor 1 and Fibroblast Growth Factor Interactions
#1601Fluorescence based reporter construct for the direct detection of TGF-beta receptor activation and modulators thereof
#1602Antibodies to activin receptor
#1603Modulation of epidermal growth factor heterodimer activity
#1604Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
#1605Anti-angiogenic compounds
#1606KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
#1607Peptide derived from vascular endothelial growth factor receptor-1 binding integrin α5β1 having proangiogenic activity
#1608Pharmaceutical preparations comprising an ALK1-Fc fusion protein
#1609Method of promoting bone growth by an anti-activin B antibody
#1610Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
#1611Insulin-like growth factor II (IGF-II) binding factors
#1612Multivalent fibronectin based scaffold domain proteins
#1613Compounds and methods of modulating angiogenesis
#1614High affinity binding site of HGFR and methods for identification of antagonists thereof
#1615ErbB interface peptidomimetics and methods of use thereof
#1616IMMUNOINTERACTIVE MOLECULES
#1617Nucleic acids encoding platelet derived growth factor receptor alpha (PDGFRA) activating mutations
#1618Processing of EphA4 polypeptide by γ-secretase activity
#1619HER-2 binding antagonists
#1620Method for screening peptides for use in immunotherapy
#1621VEGF RECEPTOR FUSION PROTEINS, THEIR PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS FOR THE EYE DISEASES
#1622NONAPOPTOTIC FORMS OF CELL DEATH AND METHODS OF MODULATION
#1623Use of TGF-Beta Antagonists to Treat or to Prevent Chronic Transplant Rejection
#1624ANTI-NOTCH1 NRR ANTIBODIES AND METHODS USING SAME
#1625TGF-BETA SUPERFAMILY BINDING PROTEINS AND MODULATION OF BONE FORMATION AND LOSS
#1626Mutated ACVR1 for diagnosis and treatment of Fibrodyplasia Ossificans Progressiva (FOP)
#1627KDR peptides and vaccines comprising the same
#1628Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
#1629Inhibitor of vascular endothelial cell growth factor
#1630NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
#1631Methods and compositions for treating inflammatory conditions
#1632Antibodies that bind to pleiotrophin growth factor receptor
#1633Variant activin receptor polypeptides
#1634NOVEL IDENTIFIED ONCOGENE WITH KINASE-DOMAIN (NOK)
#1635DNA Vaccine for Cancer Therapy
#1636Tissue protective peptides and uses thereof
#1637Diabetes Model Animal
#1638FGF2-binding peptides and uses thereof
#1639Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
#1640Plasmids coding for p185protein sequence variants and therapeutic uses thereof
#1641TGR3-Like Protein Receptor
#1642VEGF-activated ligands
#1643Method of treating lymphedema comprising administering VEGF-D
#1644Truncated Activin Type II Receptor and Methods of Use
#1645sVEGFR-2 and its role in lymphangiogenesis modulation
#1646CELL SURFACE RECEPTOR ISOFORMS AND METHODS OF IDENTIFYING AND USING THE SAME
#1647Heteroclitic analogs and related methods
#1648Activin-actrii antagonists and uses for increasing red blood cell levels
#1649Long acting VEGF inhibitors and methods of use
#1650Nucleic acid molecule encoding a fusion polypeptide capable of binding VEGF
#1651Growth factor binding constructs materials and methods
#1652Activin-ActRIIa antagonists and uses for treating multiple myeloma
#1653Pancreatic cancer targets and uses thereof
#1654Epidermal Growth Factor Receptor Polypeptides and Antibodies
#1655TARGETING VECTOR-PHOSPHOLIPID CONJUGATES
#1656Splice Variants of ErbB Ligands, Compositions and Uses Thereof
#1657Bioassays
#1658FGFR AGONISTS
#1659Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion
#1660Compositions and methods for the diagnosis and treatment of tumor
#1661Truncated EGF Receptor
#1662Long pentraxin ptx3 functional derivatives for preparing an autologous vaccine for the treatment of tumours
#1663Compounds comprising lpa
#1664Soluble HER2 and HER3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
#1665VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) PROTEIN AND GENE, MUTANTS THEREOF, AND USES THEREOF
#1666Activin-ActRIIa antagonists and uses for promoting bone growth
#1667Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof
#1668Methods and compositions for delivery of growth factor to fibrous connective tissue
#1669Methods of promoting growth of muscle tissue using ALK7
#1670Method for promoting bone growth using activin-ActRIIa antagonists
#1671ErbB receptor-derived peptide fragments
#1672Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
#1673Prosaposin as a neurotrophic factor
#1674ActRIIB Fusion Polypeptides and Uses Therefor
#1675ActRIIB Fusion Polypeptides and Uses Therefor
#1676Model animal causing the white hair development and methods relating thereto
#1677Method, compositions and classification for tumor diagnostics and treatment
#1678Human trk receptors and neurotrophic factor inhibitors
#1679Method of identifying transmembrane protein-interacting compounds
#1680Anti-Notch1 NRR antibodies
#1681Splice variants of the EGF receptor
#1682Modified chimeric polypeptides with improved pharmacokinetic properties
#1683Compositions and methods for the diagnosis and treatment of tumor
#1684Compositions and methods for the diagnosis and treatment of tumor
#1685Compositions and methods for the diagnosis and treatment of tumor
#1686Activin-actriia antagonists and uses for treating or preventing breast cancer
#1687VEGF-binding fusion proteins
#1688POLYPEPTIDE, VACCINE AND USE THEREOF
#1689Regulated transcription of targeted genes and other biological events
#1690Activin-ActRII antagonists and uses for increasing red blood cell levels
#1691GAMMA-HEREGULIN
#1692Hepatocyte growth factor receptor splice variants and methods of using same
#1693METHOD FOR DETERMINING VASOREACTIVITY
#1694COMBINATION METHODS OF INHIBITING TUMOR GROWTH WITH A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR ANTAGONIST
#1695Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
#1696MATERIALS AND METHODS FOR TREATING OCULAR-RELATED DISORDERS
#1697Compositions and methods for the diagnosis and treatment of tumor
#1698Soluble ErbB3 method of detection
#1699Compositions and methods for the treatment of respiratory disorders
#1700Compositions and Methods of Treating Tumors
#1701Methods for using chimeric vascular endothelial growth factor receptor proteins
#1702Variants derived from ActRIIB and uses therefor
#1703Prospective identification and characterization of breast cancer stem cells
#1704Recombinant anti-epidermal growth factor receptor antibody compositions
#1705Compositions and methods for the intracellular disruption of VEGF and VEGFR-2 by intraceptors
#1706Vascular endothelial cell growth factor antagonists and uses thereof
#1707NOVEL TUMOR MARKER
#1708Vascular endothelial growth factors and methods of their use
#1709Wnt antagonists and their use in the diagnosis and treatment of Wnt-mediated disorders
#1710Vascular endothelial cell growth factor antagonists and uses thereof
#1711Crystal structure of the complex of hepatocyte growth factor beta chain with met receptor and methods of use
#1712Chimeric Protein
#1713Prosaposin as a neurotrophic factor
#1714IN VITRO METHODS FOR DETECTING RENAL CANCER
#1715Soluble ErbB3 receptor isoforms
#1716Soluble ErbB3 methods of detection and antibodies
#1717Soluble ErbB3 and treatment of cancer
#1718Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis
#1719Methods for inhibiting heregulin and treating cancer
#1720Method of inducing and maintaining neuronal cells
#1721Soluble inhibitors of vascular endothelial growth factor and use thereof
#1722Ligands and libraries of ligands
#1723Soluble ErbB3 receptor isoforms
#1724Antiangiogenic active immunotherapy
#1725Immunogenic Egfr Peptides Comprising Foreign T Cell Stimulating Epitope
#1726Fusion proteins binding to VEGF and angiopoietin
#1727Netrin receptors
#1728VEGF-C ΔRΔRmutants and uses thereof
#1729Vascular endothelial growth factor C (VEGF-C) protein diagnostic
#1730TGF-beta type receptor cDNAs encoded products and uses therefor
#1731Use of VEGF inhibitors for treatment of eye disorders
#1732Method of administering and using VEGF inhibitors for the treatment of pancreatic carcinoma
#1733Method of administering and using VEGF inhibitors for the treatment of breast cancer
#1734HER-2/neu fusion proteins
#1735VEGF-RELATED PROTEIN
#1736Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
#1737Hybrid proteins with ErbB4 extracellular domain and neuregulin heparin-binding domain for targeting
#1738Treatments for pancreatic cancer metastases
#1739IGF BINDING PROTEINS
#1740Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
#1741Modified chimeric polypeptides with improved pharmacokinetic properties
#1742Methods of inhibiting ascites formation with modified chimeric VEGF polypeptides
#1743Method of administering and using VEGF inhibitors for the treatment of colorectal cancer
#1744Method of administering and using VEGF inhibitors for the treatment of renal cell cancer
#1745Method of administering and using VEGF inhibitors for the treatment of prostate cancer
#1746Antibodies which activate an erythropoietin receptor
#1747ALK1 receptor and ligand antagonist and uses thereof
#1748Method of administering and using VEGF inhibitors for the treatment of non small cell lung cancer
#1749Compositions and methods of treating disease with FGFR fusion proteins
#1750Hepatocyte growth factor receptor splice variants and methods of using same
#1751sFRP and peptide motifs that interact with sFRP and methods of their use
#1752Autocrine Growth Factor Receptors and Methods
#1753Therapeutic combination of a VEGF antagonist and anti-hypertensive agent
#1754Management of devices connected to infiniband ports
#1755Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
#1756Methods for administering tumor vaccines
#1757Epidermal growth factor receptor-derived peptides
#1758VEGF-RELATED PROTEIN
#1759Promiscuous HER-2/Neu CD4 T cell epitopes
#1760Targeting vector-phospholipid conjugates
#1761Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
#1762Prosaposin as a neurotrophic factor
#1763Vaccine
#1764ActRIIB Fusion Polypeptides and Uses Therefor
#1765Ophthalmic composition of a VEGF antagonist
#1766Antagonists of neuropilin receptor function and use thereof
#1767Immune reactivity to HER-2/protein for diagnosis and treatment of malignancies in which the HER-2/oncogene is associated
#1768METHOD FOR OBTAINING MASTOCYTE LINES FROM PIG TISSUES AND FOR PRODUCING HEPARIN-TYPE MODULES
#1769Opioid growth factor receptors
#1770Fibroblast Growth Factor Receptor-Like Molecules and Uses Thereof
#1771Splice Variant of Unc5h2
#1772Methods of screening based on the EGF receptor crystal structure
#1773Pharmaceutical compositions containing the long pentraxin PTX3
#1774In Vitro Methods for Detecting Renal Cancer
#1775Tyrosine kinse substrate
#1776P185 -encoding DNA and therapeutical uses thereof
#1777VEGF antagonist formulations suitable for intravitreal administration
#1778Crystal Structure of Erbb2 and Uses Thereof
#1779Wnt receptor compositions and methods
#1780Non-human animal alzheimer's disease model and uses thereof
#1781Compositions and methods for the diagnosis and treatment of tumor
#1782Isolation and use of solid tumor stem cells
#1783Vascular endothelial cell growth factor antagonists and uses thereof
#1784VEGF Receptor Conditional Knockout Animals and Methods of Use
#1785Isolated activin-binding ActRIIa polypeptide comprising the SEQ ID NO: 7 and uses for promoting bone growth
#1786Deglycosylated and desialidated long pentraxin PTX3
#1787Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
#1788Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
#1789Methods of producing growth factor complex
#1790GFRα3 polypeptides
#1791Method for treating cancer using a Notch4 ligand antagonist
#1792Isolation and use of solid tumor stem cells
#1793Activin receptor-like kinase-1 proteins having serine-threonine kinase domains
#1794Methods for targeting solid tumor stem cells in a solid tumor using a notch4 receptor antagonist
#1795Soluble tgf-b type III receptor fusion proteins
#1796Human platelet-derived growth factor receptors
#1797Methods for production of receptor and ligand isoforms
#1798Coiled-coil fusion proteins comprising cell receptor domains
#1799Screening and Therapy for Lymphatic Disorders Involving the FLT4 Receptor Tyrosine Kinase (VEGFR-3)
#1800NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION